How do I buy Cullinan Therapeutics, Inc. Common Stock (CGEM) stock?

Buying Cullinan Therapeutics, Inc. Common Stock (CGEM) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and verify your identity. Make a deposit. Search for the code "CGEM", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy CGEM by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

How do I tell if CGEM is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Cullinan Therapeutics, Inc. Common Stock (CGEM) Stock

Q: What is the minimum investment for CGEM on Gotrade?

On Gotrade , you don't have to buy a full share. With fractional shares, you can start investing in Cullinan Therapeutics, Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

NASDAQ · CGEM

Trade CGEM

Key stats

Market cap: $736.85M
Price / Earnings ratio: -3.5x
EPS (TTM): -$3.11
Volume: Loading
52-week high: $23.19
52-week low: $7.25

Source: third-party data provider, as of November 13, 2026

Compare with CGEM

Technical indicators

RSI 14: 33.95
MACD 12/26/9: -1.26
EMA 9 of MACD: -1.02
MACD histogram: -0.24
SMA 50: $16.35; Price below SMA 50
EMA 50: $15.40; Price below EMA 50
SMA 200: $15.84; Price below SMA 200
EMA 200: $15.02; Price below EMA 200

Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.

Analyst ratings

Analyst consensus: Buy

Based on 3 analyst ratings

Strong Sell0

Sell0

Hold0

Buy3

Strong Buy0

Third-party analyst opinion, not a recommendation from Gotrade.

Financials

Performance

Revenue

Net income

Net margin %

2021

2022

2023

2024

2025

133M88M44M0

Debt & Balance Sheet

Total assets

Total liabilities

2021

2022

2023

2024

2025

746M492M246M0

Revenue to Profit

2025

$0.0

Revenue

$0.0

Cost of revenue

$0.0

Gross profit

$0.0

Operating expenses

$-219.9M

Net income

Earnings

No data available

Source: third-party data provider

About Cullinan Therapeutics, Inc. Common Stock

No description available.

SectorHealthcare

IndustryBiotechnology

Employees109

CEOMr. Nadim Ahmed M.S.

IPO DateJan 8, 2021

HeadquartersCambridge, MA

Key Executives

Name	Title	Year Born
Mr. Nadim Ahmed M.S.	President, CEO & Director	1968
Dr. Patrick A. Baeuerle Ph.D.	Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board	1958
Ms. Mary Kay Fenton CPA	Chief Financial Officer	1964
Dr. Jeffrey Jones M.B.A., M.D., M.P.H.	Chief Medical Officer	1971
Dr. Jennifer Michaelson Ph.D.	Chief Scientific Officer	1967
Nicholas Smith	Head of Investor Relations	—
Ms. Jacquelyn L. Sumer J.D.	Chief Legal Officer, Chief Compliance Officer & Corporate Secretary	1978
Mr. Steve Andre	Chief Human Resources Officer	—
Dr. Corinne Savill Ph.D.	Chief Business Officer	1959
Ms. Rose Weldon	Senior Vice President of Corporate Affairs	—

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2021											-14.1	-6.8
2022	-18.3	+2.6	-25.2	-10.7	+1.5	+13.1	+4.5	+1.4	-1.5	+2.4	-6.3	-13.9
2023	+9.0	-2.5	-9.7	-7.3	-0.1	+5.9	-1.0	-0.3	-16.6	+11.3	-11.7	+17.7
2024	+43.0	+5.5	-7.9	+53.0	-16.4	-22.6	+15.7	+4.5	-9.6	-7.2	-14.8	-7.5
2025	-14.8	-15.6	-5.4	+10.4	+1.5	-13.9	+1.7	-1.7	-20.8	+44.3	+45.6	-3.7
2026	+18.2	+22.0	-11.1	-6.4	+22.4	+12.3	-4.5	+35.8	-29.6	+3.4	-24.8

Stocks in the same sector

Vertex Pharmaceuticals

ABEO

Abeona Therapeutics Inc.

FAQ

Buying Cullinan Therapeutics, Inc. Common Stock (CGEM) stock is now easy and instant through the Gotrade app.

Download the Gotrade app from the App Store or Google Play.
Create an account and verify your identity.
Make a deposit.
Search for the code "CGEM", then tap "Trade".
Tap the "Buy" button.
Enter the amount you want to buy. You have two options:
1. Buy CGEM by number of shares.
2. Buy fractional shares in dollars, starting from $1.
Swipe up to confirm your order, and you're done!

On Gotrade, you don't have to buy a full share. With fractional shares, you can start investing in Cullinan Therapeutics, Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

At the moment, Cullinan Therapeutics, Inc. Common Stock (CGEM) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track CGEM's performance via the price chart in the Gotrade app.

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

You can place an order any time. It goes through when the US market (NYSE/NASDAQ) opens: 9:30 AM to 4:00 PM New York time, Monday to Friday. Pre-market and after-hours trading are open too.

The market is closed on US public holidays. The Gotrade app shows whether the market is open.

There's no single perfect answer, but common approaches include:

Compare valuation (e.g., P/E, P/S) against historical averages or competitors.
Review revenue and earnings growth.
Check margins and cash flow.
Evaluate business outlook and the company's position within its industry.

You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Trade Faster. Easier. Smarter.

#ReadyGoTrade

Welcome Reward up to $1,888

Create an account and trade US stocks on Gotrade

Download app

*Terms & conditions apply

Cullinan Therapeutics, Inc. Common Stock (CGEM) Stock

Key stats

Compare with CGEM

Recent news

Does Cullinan Therapeutics (CGEM) Have the Potential to Rally 129.63% as Wall Street Analysts Expect?

Does Cullinan Therapeutics (CGEM) Have the Potential to Rally 129.63% as Wall Street Analysts Expect?

3 Growth Stocks Under $20 With Hard Catalyst Dates Ahead

3 Growth Stocks Under $20 With Hard Catalyst Dates Ahead

Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS Metastases

Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS Metastases

Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049

Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

Does Cullinan Therapeutics (CGEM) Have the Potential to Rally 129.63% as Wall Street Analysts Expect?

Does Cullinan Therapeutics (CGEM) Have the Potential to Rally 129.63% as Wall Street Analysts Expect?

3 Growth Stocks Under $20 With Hard Catalyst Dates Ahead

3 Growth Stocks Under $20 With Hard Catalyst Dates Ahead

Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS Metastases

Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS Metastases

Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049

Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049

CGEM Stock Extends Losses After Cullinan Delays Arthritis Update To December — Zipalertinib Safety Worries Linger

CGEM Stock Extends Losses After Cullinan Delays Arthritis Update To December — Zipalertinib Safety Worries Linger

Biotech Stocks Dive As Top 2% Names Take Hardest Hit

Biotech Stocks Dive As Top 2% Names Take Hardest Hit

Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

About Cullinan Therapeutics, Inc. Common Stock

Key Executives

Fundamentals

Valuation

Profitability

Trading

Technical indicators

Analyst views

Seasonality

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade